Evidence map›Paper›PMID 38149099›Full record

ArticleFrontiers in endocrinology2023

Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis.

Shuhui You, Yizhao Xie, Die Sang, Ting Luo, Peng Yuan, Fei Xu, Biyun Wang

Registry-linked trialOpen access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05572645 (Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab in HER2-Positive Metastatic Breast Cancer), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05572645 completednot on this map

Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab in HER2-Positive Metastatic Breast Cancer: a Multicenter, Retrospective Study

TypeobservationalSponsorFudan UniversityRan2022 to 2023Enrolled333ConditionsBreast CancerArmsPyrotinib Plus Trastuzumab, Pertuzumab Plus Trastuzumab
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Shuhui YouDepartment of Breast and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Yizhao XieDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Die SangDepartment of Medical Oncology, Sanhuan Cancer Hospital, Beijing, China.
Ting LuoDepartment of Head, Neck and Mammary Gland Oncology, Cancer Center, West China Hospital, Sichuan University, Sichuan, China.
Peng YuanNational Cancer Center, Tumor Hospital of the Chinese Academy of Medical Sciences, Beijing, China.
Fei XuDepartment of Medical Oncology, Sun Yat-Sen University Cancer Center, The State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.
Biyun WangDepartment of Breast and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Shanghai Medical College of Fudan University · CNSun Yat-sen University · CNCancer Hospital of Huanxing Chaoyang District Beijing · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNSichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Pyrotinib and pertuzumab are effective treatment options for HER2-positive metastatic breast cancer (HER2+ MBC). Our study was to directly compare the efficacy and safety of pyrotinib plus trastuzumab (PyroH) and pertuzumab plus trastuzumab (HP) in patients with HER2+ MBC. Methods: We conducted a retrospective examination of HER2+ MBC patients who received PyroH plus chemotherapy or HP plus chemotherapy between 2017 and 2022 at five institutions in China. Our primary endpoint was progression-free survival (PFS). Results: This study involved 333 patients, among which 161 received PyroH and 172 received HP. The utilization of PyroH as a first-line therapy for MBC was more prevalent among older patients, those with a shorter duration of disease-free interval, or those who had previously been treated with trastuzumab. Although in the first-line advanced treatment HP cohort showed numerically longer PFS (median PFS: 14.46 vs. 22.90 months, Conclusion: In conclusion, PyroH is comparable in second-line or later treatment and during brain metastasis, even having superior efficacy without taxane in real-world setting. Toxicities were tolerable in both groups. (ClinicalTrials.gov: NCT05572645).

Indexed as

Breast NeoplasmsAcrylamidesAminoquinolinesAntibodies, Monoclonal, HumanizedBridged-Ring CompoundsErb-b2 Receptor Tyrosine KinasesFemaleHumansRetrospective StudiesTaxoidsTrastuzumabAcrylamidesAminoquinolinesAntibodies, Monoclonal, HumanizedBridged-Ring CompoundsErb-b2 Receptor Tyrosine KinasespertuzumabpyrotinibtaxaneTaxoidsTrastuzumabhuman epidermal growth factor receptor 2 (HER2)metastatic breast cancer (MBC)pertuzumabpyrotinibtrastuzumab

Identifiers

PMID38149099
PMCPMC10750407
OpenAlexW4389571194

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.